Pictured above: Gregory Fenves, President; Raymond Schinazi and Leda Bassit, inventors; Patrick Reynolds, case manager; Deborah Bruner, SVP Research; Todd Sherer, AVP Research; Jill Uhl, Chief IP Officer.

Originally published here.

Start-Up of the Year: Aligos Therapeutics; Raymond Schinazi, PhD; Frank Amblard, PhD; Leda Bassit, PhD 

Aligos Therapeutics is a clinical-stage biotechnology company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos recently announced a successful $92 million private placement financing. This significant investment, which is led by a life sciences-dedicated investment firm, will help advance their innovative drug candidates. More specifically, Aligos expects to use the net proceeds from the private placement to fund the continued advancement of its Phase 2a MASH, ALG-055009 study evaluating its thyroid hormone receptor beta agonist, its CAM-E candidate, ALG-000184, as well as to fund discovery and research to broaden its pipeline of drug candidates. With this new funding, Aligos is well-positioned to continue its groundbreaking research and development, aiming to bring much-needed treatments to patients. The company expects this financial boost to extend their operational runway through the end of 2025.